T2 Biosystems, Inc., a company renowned for its rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is set to release its financial results for the first quarter of 2024 on May 6, 2024, following the market closure. The company will also provide updates on its business during this time. An investor call hosted by company management will begin at 4:30 p.m. Eastern Time on the same day.
Investors interested in attending the call can access a live and archived webcast of the event at www.t2biosystems.com on the Investors page in the Events & Presentations section. To participate in the call, dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 160751 around ten to five minutes before the start time.
T2 Biosystems is dedicated to improving patient care and reducing healthcare costs through its innovative technology solutions that enable clinicians to treat patients more efficiently. Its product lineup includes the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel, all utilizing proprietary T2 Magnetic Resonance (T2MR) technology. Additionally, T2 Biosystems has an exciting pipeline of upcoming products such as the U.S.-based T2Resistance Panel, Candida auris test, and the T2Lyme Panel for more information about them please visit www.t
